Genmab A/S (GMAB) Stock Forecast & Price Target

Genmab A/S
Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

• Genmab A/S reported three positive Phase III clinical trial readouts in October 2026, including a 50% reduction in the risk of death for petosemtamab in head and neck cancer and a 51% reduction in progression or death for EPKINLY in lymphoma, which has driven the stock to a new 52-week high of $57.29.
• The company is positioned for multiple product launches beginning in 2027, with EPKINLY showing peak sales potential above $3 billion and Rina-S targeting a peak sales potential above $2 billion, significantly expanding the addressable patient population to roughly 146,000 and 79,000 patients respectively.
• Genmab A/S demonstrated strong financial performance in its most recent quarterly report, beating analyst consensus estimates with earnings per share of $0.54 compared to the expected $0.37 and revenue of $1.16 billion against an estimate of $1.12 billion.
• Wall Street sentiment has shifted positively, with the consensus rating remaining at Moderate Buy and the average price target rising to $43.39, while major firms like JPMorgan Chase and TD Cowen recently upgraded their ratings and raised price targets following the latest clinical data.
• Short interest in the stock has decreased significantly over the past several months, dropping from over 11 million shares in late 2025 to approximately 6.6 million shares in October 2026, suggesting that investors are covering their short positions and reducing bearish pressure on the stock.